Cancer immunotherapies based on immune checkpoint blockades (ICBs), including antibodies blocking programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1), are groundbreaking treatments for several advanced and highly aggressive cancers, such as melanoma, where conventional therapies have failed. This evidence concerns the gene PDCD1 and melanoma.